Early data from a 3-year study of outcomes with radiofrequency volumetric thermal ablation (RFVTA) in patients with myomas suggests that the technology may be just as effective as laparoscopic myomectomy.
Early data from a 3-year study of outcomes with radiofrequency volumetric thermal ablation (RFVTA) in patients with myomas suggests that the technology may be just as effective as laparoscopic myomectomy. A final data analysis is pending on the research, which was were presented at the 45th AAGL Global Congress in Orlando, Florida.
Performed at a university hospital in Germany, the randomized, prospective, single-center, longitudinal analysis compared RFVTA with laparoscopic myomectomy in 50 premenopausal women aged ≥18 with symptomatic myomas. Postoperative data, based on validated questionnaires, were available for 36 of the patients.
During the 3-year period, the analysis found that in the women who had undergone RFVTA, mean transformed symptom severity scores improved by 52.9% from baseline (95% CI: 9.5, 24.2) compared with 52.1% in the women who had undergone myomectomy. Health-related quality-of-life scores improved by 8.2% in the RFVTA group versus 24.5% in the myomectomy group. Health outcome EQ-5D scores increased by 18% in the RFVTA subjects versus 17.1% in the myomectomy subjects.
Looking at outcomes related to fertility, the researchers reported 4 pregnancies with 3 deliveries and 1 pending delivery of a healthy infant in the RFTA group and 7 pregnancies with 6 deliveries of healthy infants in the myomectomy group. Patient satisfaction with surgery (moderately to very satisfied) was similar in the two groups: 64.3% for RFVTA versus 78.6% for myomectomy.
Isaacson KB, Krãmer B, Taran A, et al. Laparoscopic radiofrequency volumetric thermal ablation (RFVTA) of symptomatic myomas and laparoscopic myomectomy (LM): clinical outcomes at three years from a randomized trial of uterine-sparing techniques. Abstract 96. JMIG 2016;23(7):S40.
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More
Study shows hormone therapy offers lasting benefits for women over 65
September 12th 2024A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.
Read More